Infectious Diseases Research

Below are current clinical trials.

223 studies in Infectious Diseases Research
(all studies, either open or closed).

Filter this list of studies by location, status and more.

1. Healthcare Worker Exposure Response And Outcomes Of Hydroxychloroquine

   Rochester, Minn.

   The purpose of this study is to evaluate approximately 15,000 health care workers at risk for being exposed to COVID-19. 

2. An Open Label Study To Examine The Effects Of DAS181 Administered By Dry Powder Inhaler (DPI) Or Nebulized Formulation In Immunocompromised Subjects With Parainfluenza (PIV) Infection

   Scottsdale/Phoenix, Ariz.

   This protocol will seek to enroll up to 60 immunocompromised subjects diagnosed with parainfluenza infection.

   All subjects will have additional PK and Immunogenicity blood samples collected.

3. A Registry Of Antifungal Therapy In Adults With Either Invasive Mucormycosis Or Invasive Aspergillosis

   Rochester, Minn.

   The objective is to obtain and report outcome data for adult subjects who received systemic antifungal therapy (AFT) for the treatment of invasive mucormycosis (IM) or invasive aspergillosis (IA) caused by a non-fumigatus species.

4. A Study To Evaluate COVID Brain Advanced Imaging Network

   Rochester, Minn.

   The purpose of this study is to prospectively clarify the long-term consequences of SARS-CoV-2 infection in the CNS with multi-modal magnetic resonance (MR) imaging tracking structural, microstructural, vascular and biochemical changes.

   COVID-19 increases the risk of developing long-term inflammatory, neurodegenerative and cerebrovascular consequences.

5. A Study Comparing The Effectiveness And Safety Of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma For The Treatment Of Severe Influenza A

   Rochester, Minn.

   The purpose of this study is to assess the effectiveness and safety of giving anti-influenza immune plasma, as an addition to standard of care antivirals, to patients hospitalized with severe influenza A infection.

6. A Study of the Use of Quantiferon CMV Blood Test to Find the Length of CMV Prevention in CMV Donor (+) / Recipient (-) Solid Organ Transplant Recipients

   Rochester, Minn.

   The overall aim of this study is to evaluate the clinical utility of the QuantiFERON-CMV test in solid organ transplant recipients on CMV prophylaxis to predict development of CMV disease after completion of prophylaxis. Our hypothesis is that in CMV D+/R- solid organ transplant recipients, the development of immunity as measured by a positive QuantiFERON CMV assay will predict a lower risk of CMV disease after prophylaxis is completed.

7. An Expanded Access Study Of Sofosbuvir Combined With Ribavirin And Either With Or Without Pegylated Interferon For Treating Aggressive Post-Transplant Hepatitis C

   Jacksonville, Fla.

   The purpose of this study, is to open expanded access at specific clinical sites at the request of an investigator for the treatment of individual subjects for whom there are no other treatment options. Patients who have an aggressive, recurring hepatitis C infection following liver transplant, will be given sofosbuvir combined with ribavirin, and pegylated interferon may or may not be added at the discretion of the investigator.

8. Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin In Subjects With Chronic HCV With Advanced Liver Disease Or Post-Liver Transplant

   Jacksonville, Fla.

   The purpose of this study is to evaluate ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) in participants with chronic genotype 1 or 4 hepatitis C virus (HCV) infection. Participants will be randomized to receive 12 or 24 weeks of dosing with the LDV/SOF FDC tablet+ribavirin (RBV).

9. Presatovir In Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection Of The Upper Respiratory Tract

   Scottsdale/Phoenix, Ariz.

   This study will evaluate the effect of presatovir on respiratory syncytial virus (RSV) viral load in autologous or allogeneic hematopoietic cell transplant (HCT) recipients with an acute RSV upper respiratory tract infection (URTI), the effect of presatovir on development of lower respiratory tract complication, being free of any supplemental oxygen progression to respiratory failure, and pharmacokinetics (PK), safety, and tolerability of presatovir.

10. Evaluation Of The Efficacy And Safety Of Sarilumab In Hospitalized Patients With COVID-19 (Enrollment By Invitation Only)

    Rochester, Minn.

    Phase 2: The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with severe COVID-19.

    Phase 3: The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with severe or critical COVID-19.